Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma ...Middle East

̶ European Commission Decision Anticipated within Approximately 60 Days – NEWTON, Mass. and FLORENCE, Italy, May 20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group...

Hence then, the article about karyopharm and menarini group receive positive chmp opinion for nexpovio selinexor for the treatment of patients with refractory multiple myeloma was published today ( Friday 20/05/2022 - 03:55 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma )

Also on site :

• Peter Alexander is leaving NBC after years of being passed over for top anchor jobs: source
• London anti far-right march – latest: Police brace for unrest as thousands of protesters descend on capital
• The Japanese Concept a Psychologist Swears by To Find Purpose in Life